Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06487754
Recruiting Observational

New-onset Chronic Pelvic Pain in Transgender People Using Testosterone Therapy: an Exploratory Qualitative Study.

NCT06487754 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Grenoble
Phase
Observational
Started
2024-09-27
Last updated
2024-12-17

Condition(s) studied

Transgender PersonsPelvic PainTestosteroneGender-Affirming Care

Study summary

This descriptive qualitative study aim to describe the characteristics of pelvic pain in transgender (trans) individuals using testosterone therapy and the impact on their quality of life. This study also aim to understand the levers and obstacles to consulting a health care professional.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Being a trans masculine individual * Taking a gender affirming hormonal therapy (GAHT) * living close to Grenoble * having pelvic pain that appeared or were modified after taking GAHT Exclusion Criteria: * Subject under guardianship or subject deprived of liberty Refusal of voice recording

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
UGA Saint-Martin-d'Hères France Recruiting

More University Hospital, Grenoble trials in France

Down Syndrome, Physical Activity and Sleep Apnea Recruiting
Osteosynthesis of Fibula Fractures With a Locked Thin Plate Starting soon
Efficacy of Morphine in Reducing the Rate of Early Non-Invasive Ventilation Failure in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Phase I/IIa Recruiting
Preparation and Feasibility of Exams for Expected Studies Recruiting
Effectiveness of a Communication Training Program in Improving the Handling of Calls for Suspected Cardiac Arrest at SAMU-Centre 15. Starting soon

Other trials for the same condition

Cohort Study on Factors Associated with the Evolution of Quality of Life Among Transgender Individuals in the French Population Starting soon
Cohort of the Franco-European Multidisciplinary Institute of Endometriosis Recruiting
Gynecology Beyond Gender: Cervical Cancer Screening in Transgender Men in France Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06487754 on ClinicalTrials.gov ↗ ← All trials in France